glp-1 weight loss drug news Eli Lilly to seek approval of new weight-loss this year GLP-1 weight-loss drug popularity reaches

These observations were corroborated by single-cell calcium imaging studies in slices of arcuate nuclei, demonstrating that GLP-1MK-801 inhibits the NMDA-induced intracellular calcium surge relative to GLP-1 alone (Extended Data Fig

Updated timeline: May 2026: TRIUMPH-1 Phase 3 topline results announced Late 20262027: Remaining TRIUMPH trials complete

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure

Quality assessment of included studies Among the seven included studies, four were at low risk [33,34,35,36], and three had moderate risk [23, 25, 37] as represented in Table 2

The physiological response to oral ingestion of nutrients, involving the incretin system, is reduced in some patients with type 2 diabetes but may be augmented by administration of GLP-1 receptor agonists

The goal is to make sure patients understand the warning signs of NAION and know when to seek urgent eye care